GFM
ALNY icon

GF Fund Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

GF Fund Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.94M Sell
30,041
-421
-1% -$143K 0.17% 93
2025
Q4 		$12.1M Buy
30,462
+27,665
+989% +$12.2M 0.21% 85
2025
Q3 		$1.28M Sell
2,797
-505
-15% -$206K 0.02% 185
2025
Q2 		$1.08M Hold
3,302
– – 0.02% 207
2025
Q1 		$892K Buy
3,302
+594
+22% +$153K 0.02% 210
2024
Q4 		$637K Buy
+2,708
New +$712K 0.01% 215

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GF Fund Management's ALNY Position: Q1 2026 in Review

GF Fund Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 1.4% in Q1 2026, selling an estimated $143K and leaving 30,041 shares worth $9.94M. The position accounts for 0.17% of the portfolio, ranked #93.

GF Fund Management first reported a position in ALNY in Q4 2024 and has held it in 6 quarters since. The position peaked at $12.1M in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • GF Fund Management held 30,041 shares of Alnylam Pharmaceuticals worth $9.94M as of Q1 2026.
  • GF Fund Management sold 421 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $143K.
  • Alnylam Pharmaceuticals made up 0.17% of GF Fund Management's portfolio in Q1 2026, its #93 holding.
  • GF Fund Management first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • GF Fund Management's Alnylam Pharmaceuticals position peaked at $12.1M in Q4 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.